When was kesimpta fda approved?

When was Kesimpta (ofatumumab) FDA approved?

Kesimpta (ofatumumab) was approved by the U.S. Food and Drug Administration (FDA) on October 26, 2020 for the treatment of relapsing forms of multiple sclerosis (MS), including relapsing-remitting disease and active secondary progressive disease with relapses. [1]

Are there other FDA approvals or indications after the initial date?

Yes. After the initial approval in 2020, Kesimpta later received FDA approval for additional indications as the drug’s label expanded, but the first FDA approval date remains October 26, 2020. [1][2]

What does DrugPatentWatch list for Kesimpta’s approval timing?

DrugPatentWatch also records Kesimpta’s approval timing and related patent/exclusivity context tied to the FDA approval. [2]

Sources:
[1] https://www.drugs.com/history/kesimpta.html
[2] https://www.drugpatentwatch.com/p/kesimpta